Doctors had been hitting the right targets all along—they just didn't have the full picture.
In the long effort to understand why the immune system turns against the brain, researchers at Ludwig Maximilian University in Munich have achieved a rare kind of clarity. Using genome-wide CRISPR screening — a tool borrowed from cancer research and applied to multiple sclerosis for the first time — they have identified 23 molecular regulators governing how rogue T cells breach the blood-brain barrier, the critical act of trespass that initiates the disease's damage. The findings do not merely open new doors; they confirm that some doors medicine has been pushing on for years were, in fact, the right ones.
- Multiple sclerosis has long resisted full explanation because the molecular gatekeepers controlling immune cell infiltration into the brain had never been systematically catalogued — until now.
- A genome-wide CRISPR screen, applied to MS research for the first time, disabled genes one by one across the entire genome to reveal which molecules invite T cells in and which hold them back.
- Twenty-three key regulators emerged: five that block infiltration and eighteen that enable it, organized across three stages — adhesion to vessel walls, crossing into brain tissue, and homing deeper into the nervous system.
- Several of the identified molecules are already targeted by existing MS therapies, giving clinicians a molecular explanation for why treatments that worked in practice were working at all.
- The validated screening approach can now be aimed at other immune populations and neurological diseases, suggesting a new standard method for mapping the immune system's most consequential and destructive migrations.
Multiple sclerosis attacks the central nervous system through a process that has long been understood only in outline: autoreactive T cells breach the blood-brain barrier and trigger cascading tissue damage. What remained missing was a precise inventory of the molecular gatekeepers controlling that breach — which molecules open the door, and which ones hold it shut.
A team led by Martin Kerschensteiner and Naoto Kawakami at LMU Munich decided to answer that question systematically, deploying genome-wide CRISPR screening — a technology previously used in cancer research but never before applied to MS. Working with a rat model of the disease, they disabled genes one by one across the entire genome, combining the screen with advanced microscopy and laboratory validation to build a comprehensive molecular map of T cell infiltration.
The screen identified 23 key regulators: five that inhibit T cell migration into the brain and eighteen that facilitate it. These fall into three functional stages. First, T cells must adhere to blood vessel walls using alpha-4 integrin. Then they must cross into brain tissue, a process guided by the chemokine receptor CXCR3. Finally, they must register attractive signals that draw them deeper into the nervous system.
The findings carried an immediate practical resonance: several of the identified molecules are already targets of MS therapies in clinical use. The research confirmed that medicine had been hitting the right targets all along, while finally explaining the molecular reasons why. Beyond validation, the study establishes a screening approach that can now be turned toward other immune cell populations and other neurological diseases — a systematic method for charting the immune system's most consequential and damaging journeys.
Multiple sclerosis strikes young adults with a particular cruelty: it disables the central nervous system, the command center of the body, and it does so through a process that has long remained partly mysterious. Researchers at Ludwig Maximilian University in Munich have now mapped that process with unprecedented precision, identifying the molecular machinery that allows immune cells to breach the blood-brain barrier and begin the cascade of tissue damage that defines the disease.
The mechanism itself is well understood in broad strokes. Autoreactive T cells—immune cells that have gone rogue and begun attacking the body's own tissue—infiltrate the central nervous system and trigger a chain reaction of injury. Scientists have known this for years, confirmed through studies in animal models and in human patients. What they lacked was a complete inventory of the molecular gatekeepers that control this infiltration. Which molecules open the door? Which ones slam it shut? Until now, no one had systematically answered these questions.
A team led by Martin Kerschensteiner, director of the Institute of Clinical Neuroimmunology at LMU, and Naoto Kawakami at the Biomedical Center Munich decided to fill that gap using a tool that had never before been applied to MS research: genome-wide CRISPR screening. The technology allows researchers to systematically disable genes one by one in living organisms and observe the consequences. It had been used extensively to understand cancer, but no one had yet deployed it to map the molecular landscape of multiple sclerosis.
The researchers worked with a rat model of MS, using CRISPR to conduct an unbiased, comprehensive screen of the entire genome. They combined this with functional validation studies, advanced microscopy, and laboratory experiments to build a complete picture of how T cells breach the blood-brain barrier. The results, published in Nature Neuroscience, identified 23 key molecular regulators: five that inhibit T cell migration and eighteen that facilitate it.
These regulators fall into three functional categories, each representing a distinct hurdle the T cells must clear. First comes adhesion—the T cells must stick to the inner wall of blood vessels using a molecule called alpha-4 integrin, anchoring themselves to the endothelium like a climber gripping a rope. Next comes egress, the actual crossing from blood vessel into brain tissue, a process controlled by chemical messengers that the T cells recognize through a receptor called CXCR3. Finally, the T cells must register attractive signals from the surrounding tissue, signals that draw them deeper into the nervous system.
What emerged from this molecular mapping was both validating and pragmatic. Kerschensteiner noted that several of the key molecules the team identified are already targets of existing MS therapies in clinical use. The research essentially confirmed that doctors have been hitting the right targets all along—they just didn't have the full picture of why those targets mattered. The study provides a molecular justification for treatments already in the clinic, and it opens a door to understanding other immune cell migrations that cause neurological disease. The screening approach, now validated for its applicability to human biology, can be turned toward other questions: How do other harmful immune populations breach the blood-brain barrier? What other molecular gatekeepers remain unmapped? The work suggests that systematic, unbiased screening may become a standard tool for understanding the immune system's most consequential journeys.
Citas Notables
We lacked a comprehensive understanding of the essential molecules that regulate the migration of autoreactive T cells to the CNS.— Martin Kerschensteiner, Director of the Institute of Clinical Neuroimmunology at LMU
CRISPR technology raises the possibility of conducting comprehensive and unbiased loss-of-function screens in disease models in vivo.— Naoto Kawakami, LMU Biomedical Center Munich
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these molecules were already being targeted by existing drugs?
Because it means the field was working in the dark. Doctors had found treatments that worked, but they didn't understand the full molecular logic of why. This study provides that logic—it's validation and direction at once.
What makes CRISPR screening different from the methods researchers were using before?
The old approaches were targeted. You'd study one gene or one pathway at a time. CRISPR lets you disable thousands of genes systematically in a living organism and see what breaks. It's the difference between testing individual light switches versus mapping the entire electrical system.
If these molecules are already being targeted, what's the practical next step?
Two things. First, you can refine existing therapies—maybe you understand dosing or combination strategies better now. Second, you can look at the molecules that haven't been targeted yet. There are five inhibitors in this study. If you could enhance those, you might block infiltration even more effectively.
Why use a rat model instead of studying human cells directly?
You can't do a genome-wide screen in a human patient. But MS in rats behaves similarly to MS in humans. The researchers then validated their findings in human cells to make sure the biology translates. That's the rigor.
What does this tell us about the blood-brain barrier?
That it's not a simple wall—it's a series of checkpoints. T cells have to pass through three distinct molecular gates. Block one gate, and you slow infiltration. Block all three, and you might stop it entirely. The barrier is more sophisticated than we thought.